Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
Conference Call and Webcast Today at 4:30 p.m. ET
Royalty revenue for paritaprevir containing regimens was $17.9 million
$30 million milestone payment received from AbbVie for reimbursement approval in Japan for VIEKIRAX®
Cash and marketable securities totaled $236.6 million at December 31, 2015
WATERTOWN, Mass.-- Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2015.
Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $236.6 million at December 31, 2015. This compares to a total of $209.4 million in such accounts at September 30, 2015. Enanta expects that its current cash, cash equivalents and marketable securities will be sufficient to meet the anticipated cash requirements of its existing business for the foreseeable future.
Read more: Enanta Pharmaceuticals Inc ( ENTA )
Published: 09 February 2016
Written by Editor